Solid Biosciences (SLDB) Other Non-Current Liabilities (2018 - 2024)

Solid Biosciences (SLDB) reported Other Non-Current Liabilities of $3.4 million for Q3 2024, up 3441.67% sequentially from $96000.0 in Q4 2022.

Solid Biosciences (SLDB) Other Non-Current Liabilities (2018 - 2024) Analysis & Trends

Solid Biosciences (SLDB) has 4 years of Other Non-Current Liabilities data on file, last reported at $3.4 million in Q3 2024.

For the quarter ending Q3 2024, Other Non-Current Liabilities changed N/A year-over-year to $3.4 million; the trailing twelve-month figure through Sep 2024 stood at $3.4 million (changed N/A YoY), and the FY2022 full-year result was $96000.0, changed N/A from the prior year.
Other Non-Current Liabilities rose to $3.4 million in Q3 2024, from $96000.0 in the prior quarter.
In the past five years, Other Non-Current Liabilities ranged from a high of $3.4 million in Q3 2024 to a low of $96000.0 in Q4 2022.
A 3-year average of $1.6 million and a median of $1.3 million in 2020 frame the typical range for Other Non-Current Liabilities.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Solid Biosciences	529.40 Mn	529.40 Mn	-

Download Data